Back

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) cardiogenomics: a tertiary centre experience

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Shedding light on transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rita Amador

Hospital Santa Cruz, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Predictors and outcomes of amyloid cardiomyopathy caused by transthyretin V30 mutation
Doctor M. Pereira Santos (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Nutritional status and its impact on transthyretin cardiac amyloidosis: unraveling connection
Mrs P. Lujan Garcia (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Plasma transthyretin fractions in transthyretin cardiac amyloidosis patients undergoing tafamidis treatment
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Lifetime physical and athletic activity as novel risk factors in the development of wild-type transthyretin amyloid cardiomyopathy - a multicenter cohort study
Doctor N. Schwegel (Graz, AT)
Abstract Slides Video
Presentation thumbnail
A review of routine bone scintigraphy reports for identification of incidental myocardial tracer uptake indicating cardiac amyloidosis
Mr D. Hutt (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Shedding light on transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Transthyretin amyloid cardiomyopathy (ATTR-CM) cardiogenomics: a tertiary centre experience
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan
thumbnail
Congress Presentation
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources